Taipei

Description:

H2 provides personal and scalable chronic disease management through analytics, leading to new class of digital therapeutics. H2’s first solution Health2Sync, with over 420,000 users across Taiwan, Japan, Hong Kong, Malaysia, US, is clinically proven to help diabetics better control blood sugar and reduce risk of complications. Healthcare providers using Health2Sync has demonstrated better patient outcomes compared to the industry average. Health2Sync offers a digital “adjuvant therapy” enhancing the effects of traditional medical therapies. Furthermore, Health2Sync's data analytics enables care to scale and collaboration for third parties (insurance, med device, pharmas, etc.) in the healthcare ecosystem. H2 is pioneering in digital therapeutics, a fast growing healthtech category, which Taiwan’s ecosystem has the potential to lead in development and commercialize. In building a patient-centric platform, H2’s business partners include Ministry of Health and Welfare Taiwan, MSD, Novonordisk, and life insurers like Nanshan Life and Sompo Group of Japan, just to name a few. Health2Sync was voted world’s Top 10 Diabetes App by Healthline in 2017, 2018 and 2019.